Advisory: Alert on Trevi Therapeutics pricing withdrawn
Sept 23 (Reuters) - The alert 'Trevi Therapeutics
Announces Pricing Of $[50 Million] Public offering' issued on
Sept. 22 has been withdrawn as it was erroneously and
prematurely issued by PR Newswire.
For the correct set of alerts, click on urn:newsml:reuters.com:*:nFWN30T2YV
STORY_NUMBER: urn:newsml:reuters.com:*:nTUA8CGTTC
STORY_DATE:22/09/2022
STORY_TIME: 3:30:00
((Bengaluru Newsdesk: +1 646 223 8780))
Recent news on Trevi Therapeutics
See all newsTrevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Trevi Therapeutics Q2 net loss widens on higher R&D costs
Brief: Trevi Therapeutics Q2 Net Income USD -17.797 Million
Trevi Therapeutics Q1 net loss widens as R&D costs rise
Brief: Trevi Therapeutics Q1 Net Income USD -13.192 Million